Harmony Biosciences Holdings (HRMY) Operating Expenses (2019 - 2026)

Harmony Biosciences Holdings has disclosed Operating Expenses across 8 years of filings, most recently posting $133.6 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $133.6 million, up 38.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $498.7 million (up 28.38% YoY), and the FY2025 annual result was $461.6 million, up 25.76% from the prior year.
• Operating Expenses came in at $133.6 million for Q1 2026 at Harmony Biosciences Holdings, down from $136.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $136.7 million in Q4 2025 to a low of $43.0 million in Q1 2022.
• The 5-year median for Operating Expenses is $82.3 million (2022), against an average of $86.2 million.
• Across the five-year window, Operating Expenses decreased 22.93% in 2023 and jumped 91.5% in 2024, its largest moves.
• Harmony Biosciences Holdings' Operating Expenses stood at $53.8 million in 2022, then jumped by 58.08% to $85.1 million in 2023, then gained by 7.13% to $91.1 million in 2024, then soared by 49.98% to $136.7 million in 2025, then dropped by 2.26% to $133.6 million in 2026.
• The last three Operating Expenses figures came in at $133.6 million (Q1 2026), $136.7 million (Q4 2025), and $114.3 million (Q3 2025), per Business Quant data.